Meda AB (MDABF), a specialty pharma company, announced the European Commission has granted marketing authorization for Zyclara in the European Union. Zyclara, or imiquimod 3.75% cream, is a patented product for the treatment of actinic keratosis. The approval is valid in all EU countries.
The company said Actinic keratosis, or AK, early skin carcinoma in situ is an under-diagnosed and under-treated disease and the number of affected patients is increasing. Meda claimed Zyclara is to date the first clinically proven treatment option, which can detect and eliminate subclinical as well as clinical AK lesions on large areas of the skin.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.